ArticleThe American journal of psychiatry2019
Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.
Article in The American journal of psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.BMC psychiatry · 2026Pooled it
- Pairwise genetic meta-analyses between schizophrenia and substance dependence phenotypes reveals novel association signals with pharmacological significance.Translational psychiatry · 2022Pooled it
- Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.Schizophrenia bulletin · 2020Pooled it
- Transition rates to schizophrenia and early intervention effectiveness in substance-induced and brief psychotic disorders: a randomized controlled trial.Scientific reports · 2025Trial
- How does a family history of psychosis influence the risk of methamphetamine-related psychotic symptoms: Evidence from longitudinal panel data.Addiction (Abingdon, England) · 2023Trial
- Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Trial
- A call for action: Closing the evidence gap in management of stimulant-induced psychosis.Addiction (Abingdon, England) · 2026Article
- Demographic and clinical profiles of drug-induced psychosis: age, gender, and social context in a German cohort.European archives of psychiatry and clinical neuroscience · 2026Article
- Comparative Clinical Trajectories Across Cannabis-Related and Nonsubstance-Related Psychoses.Acta psychiatrica Scandinavica · 2026Article
- Incidence, prevalence and determinants of substance-induced mental disorders in British Columbia, 2022-2023: a population-based study.Epidemiology and psychiatric sciences · 2026Article
- Hallucinogen-Psychosis Associations Are Confounded by Baseline Psychiatric History.The Journal of clinical psychiatry · 2026Article
- Predictors of conversion to psychosis and mortality in first-episode substance-induced psychosis: a nationwide register-based study in South Korea.Schizophrenia (Heidelberg, Germany) · 2026Article
- Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis.The British journal of psychiatry : the journal of mental science · 2026Article
- Substance Use Disorders and the Psychosis Spectrum: Assessment, Clinical Challenges and Management.Journal of clinical medicine · 2026Review
- Comparing random forest and elastic net models to predict substance use disorder transitions in participants with cannabis and stimulant use: Evidence from the All of Us cohort.Drug and alcohol dependence · 2026Article
- Cannabis, psychosis, and violence: case reports and comprehensive evidence review.Frontiers in psychiatry · 2026Article
- Symptom severity and cognitive performance in patients with substance induced psychotic disorder and schizophrenia: a cross-sectional comparative study.Schizophrenia research. Cognition · 2025Article
- Exploring the implications of case selection methods for psychiatric molecular genetic studies.Molecular psychiatry · 2025Article
- Substance-induced mental disorders and discontinuation of medication for opioid use disorder.Drug and alcohol dependence · 2025Article
- The Prediction of Diagnostic Change From Bipolar Disorder to Schizophrenia and Schizophrenia to Bipolar Disorder in a Population-Based, Longitudinal, National Swedish Sample.Schizophrenia bulletin · 2025Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe objective of this study was to clarify the etiology of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample.
methodsIndividuals with a registration of substance-induced psychotic disorder between 1997 and 2015 in national medical registries (N=7,606) were followed up for a mean of 84 months. Data from medical, criminal, and pharmacy registries on first-degree through third-degree relatives were used to calculate familial risk scores for nonaffective psychosis, drug abuse, and alcohol use disorder.
resultsIndividuals with substance-induced psychotic disorder had large elevations in standardized familial risk scores for drug abuse (+1.09, 95% CI=1.02, 1.15) and alcohol use disorder (+0.98, 95% CI=0.93, 1.03) and modest elevations for nonaffective psychosis (+0.35, 95% CI=0.30, 0.41). The cumulative risk for progression to schizophrenia was 11.3%; it was lowest for alcohol-induced and highest for cannabis-induced psychotic disorder, and it was predicted by early age at diagnosis of substance-induced psychotic disorder, male sex, and further registrations for episodes of drug abuse, alcohol use disorder, and substance-induced psychotic disorder. A risk prediction model found that 47% of individuals who converted to schizophrenia were in the upper 20% of risk. Familial risk scores for drug abuse and alcohol use disorder did not significantly discriminate those who converted to schizophrenia from those who did not, while familial risk score for nonaffective psychosis did (0.67, 95% CI=0.40, 0.95, versus 0.33, 95% CI=0.28, 0.39). Familial risk scores for nonaffective psychosis were indistinguishable between individuals with schizophrenia with and without prior substance-induced psychosis. Assignment of early retirement by the Swedish Social Insurance Agency strongly discriminated between individuals with substance-induced psychotic disorder with and without later schizophrenia.
conclusionsSubstance-induced psychotic disorder appears to result from substantial drug exposure in individuals at high familial risk for substance abuse and moderately elevated familial risk for psychosis. Familial risk for psychosis, but not substance abuse, predicts progression from substance-induced psychosis to schizophrenia. Schizophrenia following substance-induced psychosis is likely a drug-precipitated disorder in highly vulnerable individuals, not a syndrome predominantly caused by drug exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.